REMARKS

Claims 1-29 remain in this application.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

In the unlikely event that the transmittal letter is separated from this document and/or the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-1189**, referencing attorney docket no. 126881206100. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Date: _August 9, 2001_

By: _____
Antoinette F. Konski
Reg. No. 34,202

Respectfully submitted,

McCutchen, Doyle, Brown & Enersen
Three Embarcadero Center, Suite 1800
San Francisco, California 94111

Telephone: (650) 849-4950
Facsimile: (650) 849-4800

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at line 16 of page 2 has been amended as follows:

Polycystic kidney disease (PKD) is a common inherited condition for which there are no cures and few effective therapies. The disease can be transmitted as an autosomal dominant or recessive defect. The dominant form of PKD is one of the most prevalent life-threatening genetic diseases, affecting approximately 600,000 Americans and more than 12 million families worldwide. The National Institutes of Health estimates that one in 400 to 1,000 persons has autosomal dominant polycystic kidney disease (ADPKD), and one in 10,000 to 40,000 individuals has autosomal recessive polycystic kidney disease (ARPKD). More than fifty percent of the affected individuals are expected to develop renal failure by the age of 60; consequently, ADPKD currently accounts for 4 to 8 percent of the renal dialysis and transplantation cases in the United States and Europe (Robinson and Hawkins, eds. (1981) [Proc. Dialysis and Transplant Assn.] PROC. EUROPEAN DIALYSIS AND TRANSPLANT ASSN. 17:20).

Paragraph beginning at line 1 of page 2 has been amended as follows:

Most forms of PKD are characterized by the development of fluid-filled cysts from the nephrons and collecting ducts of affected kidney tissue, which results in grossly enlarged kidneys with progressively weakened renal-concentration ability. Cyst development can also occur in other ductal organs such as liver, pancreas and spleen. Further systemic manifestations may include gastrointestinal, cardiovascular, and musculoskeletal abnormalities, such as colonic diverticulitis, berry aneurysms, hernias, and mitral valve prolapse (Gabow, et al. (1989) Adv. Nephrol. **18**:19-32 and Gabow [et al.] (1993) New Eng. J. Med. **329**:332-342). Hypertension and endocrine dysfunction are also common in ADPKD patients, appearing even before symptoms of renal insufficiency.

Paragraph beginning at line 11 of page 2 has been amended as follows:

Recently, a few genetic attributes of PKD have been identified. Linkage studies and mutation analysis have indicated a causative gene (PKD1) located on chromosome 16p13.3, which is responsible for eighty-five percent of ADPKD cases (Reeders et al. (1985) Nature **317**:542-544; Breuning et al. (1987) Lancet [ii] **2(8572)**:1359-1361). A large number of mutations in the PKD1 gene sequences have been found to be associated with the onset of polycystic kidney disease. Apart from large genomic deletions that eliminate PKD1, the mutations that have been defined clearly in ADPKD1 families appear to result in the transcription of a truncated or abnormal message RNA from the affected allele (The American PKD1 Consortium (1995) Human Mol. Genet. **4**:575-582). These gene sequence alterations include small in-frame Application No. 09/830,506 deletions, deletions and

52055895_1   7

Docket No. 126881206100
Serial No.: 09/830,506

missense mutations that result in premature termination, splice-site mutations and chromosomal translocations which interrupt the gene. Most of the other ADPKD cases can be attributed to PKD2 (Kimberling W.J. et al. (1993) Genomics **18**:467-472; Mochizuki I. et al. (1996) Science **272**:1339-1342), with less than one percent due to the third locus for ADPKD, which has not been mapped yet.

Paragraph beginning at line 9 of page 3 has been amended as follows:

Highly conserved motifs residing in the N-terminal extracellular domain include two leucine-rich repeats (LRRs) with cysteine-rich flanking regions, immunoglobulin (Ig)-like repeats, and a C-type lectin domain. Leucine-rich repeats (LRRs) are commonly found in the leucine-rich glycoprotein family, which takes part in a diversity of physiological events. Proteins sharing this homology include but are not limited to α2-glycoprotein, members of the GPIb.LX complex (von Willebrand factor receptor), *Drosophila chaoptin,* toll and slit ([Burns et al.] The American PKD1 Consortium (1995) Human Mol. Genet. **4**:575-82). Many LRR proteins are localized in the plasma membrane or extracellular matrix and are thought to be involved in cell adhesion and developmental regulation (Kobe et al. (1994) Trends Biochem. Sci. **19**:415-21). At least half of the LRR-containing proteins identified thus far have been shown to be involved in signal transduction, as for example the receptor tyrosine kinases Irk, TrkB, and TrkC. In addition, C-type lectin domains are known to mediate calcium-dependent, carbohydrate binding in cell-cell and cell-matrix adhesion (The International Polycystic Kidney Disease Consortium (1995) Cell **81**:289-98).

Paragraph beginning at line 2 of page 4 has been amended as follows:

Elucidation of the biological functions of a gene often begins with examining the expression pattern of the gene product. Polyclonal and monoclonal antibodies directed against peptide or fusion proteins, mainly from the C-terminal region of polycystin, have been used to study the expression of polycystin in human and animal tissues (Ward et al. (1996) Proc. Natl. Acad. Sci. USA **93**:1524-1528; Griffin et al. (1996) Proc. Assoc. Am. Physicians **108**:185-197; Peters et al. (1996) Lab. Invest. **75**:22 1-230; Geng et al. (1996) J. Clin. Invest. **98**:2674-2682; [Paulson] Palsson et al. (1996) Molec. Med. **2**:702-711; Van Adelsberg et al. (1997) Am. J. Physiol. **272**:F602-F609; Ibraghimov-Beskrovnaya et al. (1997) Proc. Natl. Acad. Sci. USA **94**:6397-6402; Geng et al. (1997) Am. J. Physiol. **272**:F451-F459; Griffin et al. (1997) Kidney Int. **52**:1196-1205; Geng et al. (1997) J. Am. Soc. Nephrol. **8**:372A). These studies indicate that polycystin is expressed in many tissues in addition to the kidney and the liver. These include the epithelial cells of pancreatic and mammary ducts, intestinal crypts, urothelium and bronchioles; basal keratinocytes of the skin; neural crest, brain, neural plexuses and adrenal medulla; myocardium vascular smooth muscle of elastic and distributive arteries; and certain endothelial cells (Griffin et al. (1996) Proc. Assoc. Am. Physicians **108**:185-197; Geng et al. (1996) J. Clin. Invest. **98**:2674-2682; Ibraghimov-Beskrovnaya et al. (1997) Proc. Natl. Acad. Sci. USA **94**:6397-6402; Geng et al. (1997) Am. J. Physiol. **272**:F451-F459; Griffin et al. (1997) Kidney Int. **52**:1196-1205; Griffin et al. (1997) J. Am. Soc. Nephrol. **8**:616-626; O'Sullivan et al. (1997) J. Am. Soc.

Nephrol. **8**:376A). Studies on the immunolocalization of polycystin in the kidney, however, yielded ambiguous results. For instance, there are conflicting observations as to whether polycystin is expressed in the glomeruli region of the kidney nephrons. There are also differing views as to whether polycystin is localized to basal and apical membranes of renal epithelial cells, and to what degree it is present in the cytoplasm.

Paragraph beginning at line 22 of page 43 has been amended as follows:

The polycystic kidney disease 1 (PKD 1) gene encodes a novel protein with multiple cell recognition domains. Hughes J. et al. (1995) Cell **10**:151-[159]160. The analysis of the three-dimensional structure of a single repeat showed that it is not a true member of Ig superfamily, although it has a characteristic β-sandwich topology. Bycroft M. et al. (1999) EMBO J. **18**:297-305. Domains with this Ig-like fold are present in proteins as diverse as matrix proteins, receptors and enzymes, and in each case they have been shown to interact with extremely different ligands varying from small peptides (e.g., HLA) to giant proteins (e.g., titin oligomer). Bork A. et al. (1994) J. Mol. Bid. **242**:309-320.

Paragraph beginning at line 1 of page 44 has been amended as follows:

Using antibodies against three different regions of polycystin- 1: N-terminal (LRR), C-terminal, and the middle region (REJ), the experiments described herein clearly showed that polycystin-1 was predominantly expressed at sites of cell-cell contact in kidney epithelial cells, as was the case for endothelial cells. The homophilic binding potential of several Ig-like a b domains, i.e., Ig^a, Ig^b and Ic^e, containing 4, 5 and 6 domains, as clusters were analyzed as described below. Each region was translated *in vitro* and tested for the ability to bind to each region including itself in the form of immobilized fusion protein. The binding properties of all combinations were quantitatively analyzed as a percentage of binding of *in vitro* translated protein. In this type of assay the fusion proteins are present in a vast excess compared to the amount of the translated probe. Therefore, theoretically almost all of the translated probe should bind to immobilized fusion protein, even if binding is weak. Phizicky, F.M. & Fields, S. (1995) Microbiological Reviews **59**:94-123. In practice, deviations from quantitative binding occur if not all of the immobilized protein or/and *in vitro* translated probe is functionally active. Nevertheless, a functionally relevant interaction should result in significant retention of ligand. For example, estimates from affinity chromatography binding experiments on the N-NusA, NusA-RNA polymerase and RAP3O/74-RNA polymerase II interactions indicate that at least 50% of these proteins are available for binding. [Formoza] Formosa, I. et al. (1991) Meth. Enzymol. **208**:24-45.

Paragraph beginning at line 15 of page 45 has been amended as follows:

To adequately assess the significance of the Ig-like domain homophilic interactions under consideration, they were compared them side by side with known interactions. One of those was the interaction between p53 and SV40 large T-antigen, which is known to be functionally significant. Lane D.P. et al. (1979) Nature **278**:261- [262]263 and Iwabuchi K.

et al. (1993) Oncogene **8**:1693-1696. The bound fraction of T-antigen comprised approximately 45% of the total probe in this system. The interaction between the PKD 1 and PKD2 gene products also was used as a reference. [Quian] Qian F. et al. (1997) Nature Genetics **16**:179-183 and Tsiokas L. et al. (1997) Proc. Natl. Acad. Sci. USA **94**:6965-6970. This interaction was initially identified by the two-hybrid assay and was further characterized using the *in vitro* binding assay. Approximately 1.5% of the input polycystin-1 probe bound to immobilized polycystin-2, while 6% of the labeled ligand was bound in the reverse combination. [Quian] Qian F. et al. (1997) Nature Genetics **16**:179-183. Similarly, a weak PKD2-PKD1 gene product interaction was detected which never exceeded ~ 1% of binding in different buffer compositions in different buffer compositions. Thus, the strength of the homophilic interactions between the various Ig-like regions of polycystin-1 as measured *in vitro* is more comparable to the known functionally significant p53-1 antigen binding rather than to the weaker and likely transient interaction between polycystin-1 and -2.

Paragraph beginning at line 11 of page 46 has been amended as follows:

The formation and progression of ADPKD cysts is characterized by increased cell proliferation, resulting in expansion of the epithelium, which displays a relatively undifferentiated appearance. Grantham J. (1996) Amer. J. Kidney Diseases **28**:788-803 and Avner E.D. (1993) J. Cell Sci. **17**:217-222. The role of polycystin-1 in mediating cell-cell interactions, where such interactions are fundamental for cellular functions of proliferation, differentiation and maturation, is supported by a recent study of a targeted PKD1 mutation in mice. Lu W. et al. (1997) Nature Genetics **17**:179-181. This study demonstrates that polycystin1 is critical in the establishment and maturation of normal tubular architecture. Lu W. et al. (1997), *supra*. It has been shown that the expression of polycystin-1 is continued into adult life at a lower level, where its functional activity might be required for cells to remain tightly associated in the epithelium. Peters D.J.M. et al. (1996) Laboratory Investigation 75:22 1-230; Ibraghimov-Beskrovnaya 0. et al. (1997) Proc. Natl. Acad. Sci. USA **94**:6397-[640]6402; Weston B.S. et al. (1997) Histochemical Journal **29**:847-856 (1997); and Ward C.J. et al. (1996) Proc. Natl. Acad. Sci. USA **93**:1524-1528. In addition, it is known that cell adhesion proteins play an important role in intercellular signaling. Gumbiner B.M. (1996) Cell **84**:345-357. The results presented herein show that the loss of intercellular interactions due to a mutated polycystin- 1 can be an important step in molecular cystogenesis.

52055895_1

10